Free Trial
→ URGENT: If you own a home, please review the map below. (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
$0.41
$1.19
$0.37
▼
$14.09
$2.15M2.04220,545 shsN/A
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
$1.23
+1.2%		$1.39
$1.02
▼
$1.91
$65.49M1.52520,144 shs157,192 shs
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
$0.41
+5.5%		$0.46
$0.26
▼
$15.40
$5.38M0.61289,430 shs2,036 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
0.00%0.00%0.00%0.00%-89.30%
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
-3.97%-5.10%-10.37%-3.97%-14.79%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
+14.35%+14.35%-21.50%-23.76%-96.64%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
$0.41
$1.19
$0.37
▼
$14.09
$2.15M2.04220,545 shsN/A
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
$1.23
+1.2%		$1.39
$1.02
▼
$1.91
$65.49M1.52520,144 shs157,192 shs
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
$0.41
+5.5%		$0.46
$0.26
▼
$15.40
$5.38M0.61289,430 shs2,036 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
0.00%0.00%0.00%0.00%-89.30%
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
-3.97%-5.10%-10.37%-3.97%-14.79%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
+14.35%+14.35%-21.50%-23.76%-96.64%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
2.00
HoldN/AN/A
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
2.80
Moderate Buy$4.33253.74% Upside
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
2.20
Hold$53.3312,908.13% Upside

Current Analyst Ratings Breakdown

Latest RVPH, PMVP, and CLSD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/24/2026
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E+) ➝ Sell (D-)
9/9/2026
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D-) ➝ Sell (E+)
9/4/2026
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$5.00
(Data available from 11/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
$3.33M0.64N/AN/A($7.68) per share-0.05
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
N/AN/AN/AN/A$1.07 per shareN/A
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
N/AN/AN/AN/A$1.48 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
-$34.35M-$5.19N/AN/AN/A-665.19%N/A-124.15%N/A
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
-$77.74M-$1.54N/AN/AN/AN/A-91.39%-72.22%N/A
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
-$19.86M-$1.85N/AN/AN/AN/A-391.58%-119.08%11/16/2026 (Estimated)

Latest RVPH, PMVP, and CLSD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/16/2026Q3 2026
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
-$0.29N/AN/AN/AN/AN/A
11/10/2026Q3 2026
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
-$0.3367-$0.52-$0.1833-$0.52N/AN/A
8/14/2026Q2 2026
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
-$0.3875-$0.34+$0.0475-$0.34N/AN/A
8/13/2026Q2 2026
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
-$0.3850-$0.19+$0.1950N/AN/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
N/AN/AN/AN/AN/A
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
N/AN/AN/AN/AN/A
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
N/A
3.87
3.87
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
N/A
9.81
7.70
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
N/A
2.08
2.08

Institutional Ownership

CompanyInstitutional Ownership
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
18.75%
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
90.20%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
63.18%

Insider Ownership

CompanyInsider Ownership
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
6.70%
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
10.15%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
8.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Clearside Biomedical, Inc. stock logo
CLSD
Clearside Biomedical
305.23 million4.89 millionOptionable
PMV Pharmaceuticals, Inc. stock logo
PMVP
PMV Pharmaceuticals
5453.46 million48.03 millionOptionable
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
1413.11 million11.67 millionNo Data

Recent News About These Companies

Reviva Pharmaceuticals Reports FDA Feedback Timeline, New Brilaroxazine Patent Progress and Q3 2026 Results
November 12 at 8:30 PM  |  quiverquant.comQ
Reviva Reports Third Quarter 2026 Financial Results and Recent Business Highlights
November 12 at 8:13 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/13/3402358/0/en/reviva-reports-third-quarter-2026-financial-results-and-recent-business-highlights.html
Reviva Pharmaceuticals (RVPH) Projected to Release Earnings on Thursday
November 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31179414
Reviva Pharmaceuticals op Lytham Partners: brilaroxazine vordert
September 29, 2026  |  nl.investing.comhttps://nl.investing.com/news/transcripts/reviva-pharmaceuticals-op-lytham-partners-brilaroxazine-vordert-93CH-926870
Reviva Pharmaceuticals alla conferenza Lytham Partners: avanza brilaroxazine
September 29, 2026  |  it.investing.comhttps://it.investing.com/news/transcripts/reviva-pharmaceuticals-alla-conferenza-lytham-partners-avanza-brilaroxazine-93CH-3567624
Reviva to Participate in the Lytham Partners Fall 2026 Investor Conference
September 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/22/3366238/0/en/reviva-to-participate-in-the-lytham-partners-fall-2026-investor-conference.html
RVPH: Patent Filed for New Formulation
August 17, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/rvph-patent-filed-for-new-formulation-165800148.html
Reviva Pharmaceuticals: Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 13, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69299534-reviva-pharmaceuticals-reviva-reports-second-quarter-2026-financial-results-and-recent-business-highlights-399.htm
Reviva Pharmaceuticals Files U.S. Patent Application for New Brilaroxazine Formulation, Expects FDA Feedback in Q4 2026
August 12, 2026  |  quiverquant.comQ
Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/12/3344112/0/en/reviva-reports-second-quarter-2026-financial-results-and-recent-business-highlights.html
Reviva Pharmaceuticals to Present at the Life Sciences Investor Forum on June 24th
June 23, 2026  |  financialpost.comF
Reviva Pharmaceuticals to Present at the Life Sciences Investor Forum on June 24th
June 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/23/3315885/0/en/reviva-pharmaceuticals-to-present-at-the-life-sciences-investor-forum-on-june-24th.html
Reviva to Participate in Fireside Chat at A.G.P.’s Annual Healthcare Company Showcase
May 18, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/reviva-participate-fireside-chat-g-120000847.html
Reviva to Participate in Fireside Chat at A.G.P.'s Annual Healthcare Company Showcase
May 18, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/18/3296578/0/en/reviva-to-participate-in-fireside-chat-at-a-g-p-s-annual-healthcare-company-showcase.html
OTC Listing Leaves Reviva Pharmaceuticals Shares Vulnerable to Thin Trading and Volatile Price Swings
May 15, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/otc-listing-leaves-reviva-pharmaceuticals-shares-vulnerable-to-thin-trading-and-volatile-price-swings?utm_source=marketbeat.com&utm_medium=referral
Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/13/3294478/0/en/reviva-reports-first-quarter-2026-financial-results-and-recent-business-highlights.html
Analysts Offer Insights on Healthcare Companies: Reviva Pharmaceuticals Holdings (RVPH) and Merck & Company (MRK)
April 21, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/MRK-N/pressreleases/1420046/
Maxim Turns Cautious on Reviva Pharmaceuticals Holdings, Inc. (RVPH) Despite Phase 3 Progress Plans
April 20, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/maxim-turns-cautious-on-reviva-pharmaceuticals-holdings-inc-rvph-despite-phase-3-progress-plans-1742248/
Reviva Pharmaceuticals: Reviva Announces Letter to Shareholders
April 15, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-04/68205477-reviva-pharmaceuticals-reviva-announces-letter-to-shareholders-399.htm
Reviva Pharmaceuticals Holdings, Inc. Updates Shareholders on Strategic Direction and Brilaroxazine Development
April 15, 2026  |  quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

Clearside Biomedical stock logo

Clearside Biomedical NASDAQ:CLSD

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

PMV Pharmaceuticals stock logo

PMV Pharmaceuticals NASDAQ:PMVP

$1.23 +0.02 (+1.24%)
As of 12:03 PM Eastern
This is a fair market value price provided by Massive. Learn more.

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

Reviva Pharmaceuticals stock logo

Reviva Pharmaceuticals NASDAQ:RVPH

$0.41 +0.02 (+5.45%)
As of 11:04 AM Eastern

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas